SPCX Fades a 28% Relief Rally With 319 Million More Shares Due August 20

The Rally This Move Is Unwinding

To understand a 4.35% fade you have to understand what came before it. SPCX opened August 3 at $114.53 and closed August 10 at $138.74, a 21.14% weekly gain. By the August 12 close it had reached $146.15. That is roughly 28% in seven sessions, in a $1.85 trillion company.

The fuel was a non-event. The August 6 lockup expiration released 911.5 million shares — more than doubling the publicly available float — and the consensus expectation was a flush. Instead, the stock rose 6% on the day because insiders did not meaningfully sell. The market read that as a confidence signal and repriced accordingly. A Semi Analysis research note arguing SpaceX could credibly build 10GW of compute by end-2027 gave the bid an narrative to run on.

That is a behavioral read, not a structural one. Insiders declining to sell into one date tells you nothing binding about the next one. It has to be re-proven every tranche, and that is exactly what is being priced right now.

August 20 and the Supply Calendar Behind It

The next scheduled release is 319 million shares on August 20, a 70-day fixed milestone worth about 2.44% of the basic share-count base. On its own that is small — roughly a third of what already cleared on August 6.

The calendar after it is the real issue. Roughly 700 million shares are scheduled for September and close to that again in October. August through December is the densest stretch of the 180-day lock-up release schedule. August 20 matters less as a supply shock than as the next data point on whether insiders keep sitting still, and traders are de-risking into it rather than waiting to find out.

This is also not new terrain for the stock. SPCX fell under its $135 IPO price in mid-July as the lockup calendar came into focus, bottomed near $104, and has only just clawed back above the IPO price. The June 16 intraday high of $225.64 is still a long way up.

The Fundamental Argument Is Genuinely Unresolved

Q2 was not a bad quarter. Revenue came in at $7.81 billion against $4.1 billion a year earlier, up 92% and ahead of the $6.93 billion consensus. Net loss narrowed to $541 million from $1 billion, and the $0.09 per-share loss beat the $0.26 estimate outright.

The market ignored all of it and focused on one line. Capex hit $18.37 billion, with $15.83 billion of that going to AI infrastructure — about 39% above the $13.22 billion analysts modeled. The stock closed down 13.6% on the print, an all-time closing low. First-half net loss stands at $4.82 billion.

The sell side is split in an unusually wide way. Consensus sits at Moderate Buy with an average target around $229, but the distribution is 2 Strong Buy, 25 Buy, 8 Hold and 5 Sell, and the individual calls barely overlap. Morgan Stanley's Adam Jonas holds a $300 base target with a $600 bull case built on the $60 billion Cursor acquisition, modeling Cursor ARR at $8 billion by year-end and $33 billion by 2030. Piper Sandler, meanwhile, cut its target to $140 from $156, and RBC moved to Hold. When targets on the same name run from $140 to $600, price is going to be decided by flows and positioning, not by the models.

Levels and Perp Structure

SPCX trades at $141.60 after a 13-hour slide of 4.35%. The reversal came off $146.15 — and the 50-day moving average sits at $143.08, which is where the rally stalled and turned. That is a clean technical rejection, not a random fade.

Below, the August 13 session low of $139.76 is the immediate reference, then the $135 IPO price, which has functioned as the psychological pivot for this entire post-IPO range. Cash volume ran 119.3 million shares against a 116.3 million average — active, but not a liquidation.

On the Hyperliquid side, the HIP-3 perp turned over $315.8 million in 24 hours. That is a deep enough book that the perp is tracking the underlying rather than leading it, so the August 20 unlock and the September calendar behind it are the variables that matter here, not perp-native positioning.